In statin-intolerant adults with, or at risk for, CV disease, bempedoic acid reduced MACE at a median 41 mo.
Where this comes from
- Record sourced from PubMed, PMID 37399554.
- Also identified by DOI 10.7326/J23-0044.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nissen SE, Lincoff MA, Brennan D, et al; CLEAR Outcomes Investigators. <b>Bempedoic acid and cardiovascular outcomes in statin-intolerant patients.</b> N Engl J Med. 2023;388:1353-1364. 36876740.
Medical subject headings
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Cardiovascular Diseases